In April 2025, Aaron Sneed, founder of Defense Operations & Engineering Solutions Inc. (DOES), confronted a mounting crisis as US–China trade tensions escalated. With new tariffs threatening the supply of Chinese pharmaceutical ingredients and exposing deep vulnerabilities in global drug manufacturing, Sneed revisited a long-standing concern: America’s dependence on foreign sources for critical medications. Having witnessed similar disruptions during the COVID-19 pandemic, he now faced a pivotal decision. Should DOES rapidly scale domestic active pharmaceutical ingredient production despite regulatory and financial hurdles? Or should it pursue alternative strategies such as partnerships or temporary imports?
看看哪些人也有訂購？